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Macrophages: central regulators of iron balance
Elena Gammella, Paolo Buratti, Gaetano Cairo* and Stefania Recalcati
Macrophages are important to immune function and also actively participate in iron homeostasis. The
involvement of splenic and liver macrophages in the processing of eﬀete erythrocytes and the
subsequent return of iron to the circulation is well established, and the molecular details of iron
recycling have been characterized recently. Another important aspect regarding iron handling by
macrophages is their capacity to act as immune cells, which involves the inflammatory response, as well
as other pathological conditions in which macrophages are central. This review discusses the latest
advances in macrophage iron traﬃcking and the pathophysiological consequences of altered iron
homeostasis in these cells.
Introduction
Macrophages are diﬀerentiated cells of the mononuclear pha-
gocyte system; they have a variety of functions in distinct
locations.1 The major role of macrophages is associated with
the innate immune response, as macrophages are essential for
immune surveillance and the induction of the inflammatory
response. However, macrophages also fulfill important homeo-
static functions, such as the clearance of apoptotic cells and
cellular debris, and iron recycling.2 This review focuses on the
latter function; we consider the most recent and relevant
insights into the molecular aspects of iron traﬃcking, and also
examine the pathophysiological implications of altered iron
homeostasis in the various subsets of macrophages.
Role of macrophages in systemic iron traﬃcking
In humans, daily intestinal iron absorption (B2 mg) is suﬃ-
cient to counterbalance physiological loss, but it is clearly
inadequate to provide suﬃcient iron to meet the ten-fold
higher requirement for hemoglobin synthesis and erythro-
poietic cell proliferation. Erythroid cells acquire almost exclu-
sively transferrin-bound iron, which is replenished by the
recycling activity of macrophages. Macrophages in the reticu-
loendothelial system process old and/or defective red blood
cells and return hemoglobin-derived iron to the circulation3
(Fig. 1). These specialized phagocytes are resident macrophages
localized in the liver (Kupﬀer cells) and spleen red pulp, which
(at least in the spleen) require the Spi-C transcription factor for
their development and to exert their iron recycling function.4
Moreover, it has been shown that heme-regulated eIF2 kinase,
which regulates protein synthesis to ensure that globin chains are
synthesized in appropriate amounts, is also expressed in macro-
phages and is required for their maturation and erythrophagocytic
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activity.5 Notably, the phagocytosis of all types of blood cells by
macrophages can be stimulated by interferon-g under inflam-
matory conditions such as hemophagocytic lymphohistiocytosis,
which can lead to cytopenias as well as severe and acute
anemia.6 Such stimulation represents an additional mechanism
at the basis of anemia of inflammation, based on increased red
cell destruction (in the absence of hemolysis and hemorrhage),
rather than impaired production.
Ferroportin exports iron from macrophages (Fig. 2). To date,
it has been the only known protein that transports ferrous iron
from the cytoplasm across the plasma membrane (see Ward7
and Mitchell8 for a review). Transferrin, a circulating carrier
that delivers iron for erythropoiesis and also satisfies the
requirements of all other cells in which iron is used by proteins
that perform essential functions, such as DNA synthesis (e.g.,
ribonucleotide reductase) or mitochondrial energy production
(a number of proteins that contain heme groups and iron–
sulfur clusters), binds only ferric iron efficiently (see Andrews9
for review). Therefore, iron exit from macrophages requires the
ferroxidase activity of circulating ceruloplasmin. Iron recycling
is negatively modulated by the interaction of ferroportin with
hepcidin, a liver-derived peptide that induces the internaliza-
tion and degradation of ferroportin, thus impairing its export
activity (reviewed by Hentze10 and Pantopoulos11). Hepcidin
also modulates intestinal iron absorption, and therefore it is
the key regulator of systemic iron homeostasis: it is induced
mainly by increased iron stores and inflammatory stimuli, and
is decreased during conditions of high erythropoietic activity.12
Hepcidin levels are inappropriately low in iron-loaded heredi-
tary hemochromatosis patients, which accounts for the obser-
vation that macrophages are paradoxically iron-deficient in
individuals with body iron overload.13
Iron traﬃc inside macrophages
Macrophages in the red pulp of the spleen and Kupﬀer cells in
the liver recognize alterations in the red cell surface that may
include the modification of membrane determinants, such as
proteins (e.g., Band 3), sialic acid, phosphatidylserine, or
enhanced membrane rigidity that impairs deformability, and
then capture and internalize red cells with a process similar
to classic phagocytosis. Thus, the ingested erythrocytes are
engulfed in phagolysosomes, in which oxidants and hydrolytic
enzymes trigger the release of hemoglobin and then heme.14
Until recently, the successive step (the appearance of heme-
derived iron in the cytosol) remained obscure because heme
oxygenase 1 (HO-1), an inducible enzyme that cleaves heme to
yield CO, iron, and biliverdin, is localized to the endoplasmic
reticulum. The possibility that the endoplasmic reticulum con-
tributes membrane constituents (and therefore also HO-1) to the
formation of the phagocytic vacuole membrane was supported
by observations that the iron transporters natural resistance
associated macrophage protein (Nramp1) and divalent metal
transporter 1 (DMT1) are recruited and localized at the erythro-
phagosomal membrane, where they promote eﬃcient iron recy-
cling.15 However, another report did not confirm the detection of
DMT1 in the membrane of erythrophagosomes,16 and the
hypothesis was in contrast with the topology of HO-1, whose
catalytic domain faces the cytosol. This discrepancy has been
resolved by a recent study that provided evidence showing how
heme crosses the phagolysosomal membrane to be delivered to
HO-1 for degradation. Heme-responsive gene 1 protein homolog
(HRG1), which is highly expressed in macrophages and specifi-
cally localizes to the phagolysosomal membranes, transports
heme from the phagolysosome and is essential for heme-iron
recycling in macrophages17 (Fig. 2). Notably, lack of HO-1 caused
the death of liver and spleen macrophages accompanied by
abnormalities of iron homeostasis and kidney damage inmice;18
however, the phenotype was milder in the single human patient
lacking HO-1.19 Excessive heme leads to tumor necrosis factor
a-dependent and reactive oxygen species (ROS)-dependent pro-
grammed necrosis in macrophages, and cytotoxicity is exacer-
bated by the lack of HO-1.20 It has been demonstrated that feline
leukemia virus, subgroup C, receptor (FLVCR) exports cytoplas-
mic heme from macrophages.21
Gaetano Cairo
Gaetano Cairo is full professor of
General Pathology at the
University of Milan School of
Medicine, Italy. He obtained a
university degree in Biological
Sciences from the University of
Pavia and in Agricultural
Sciences from the University of
Milan. His long standing
research interest focuses on the
molecular control of genes of iron
homeostasis under patho-
physiological conditions. Stefania Recalcati
Stefania Recalcati earned a MD
in 1995 from the University of
Milan. In 1999 she completed
her training in Gastroenterology
at the University of Milan, and
was licensed as a gastro-
enterology specialist. In 2003
she received a PhD in Gastro-
enterology from the same
university. She is presently
Assistant Professor at the
Department of Biomedical
Sciences for Health of the
University of Milan, Italy, where
she is in charge of a project investigating macrophage iron
metabolism in health and disease.
Minireview Metallomics
Pu
bl
ish
ed
 o
n 
29
 M
ay
 2
01
4.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
 S
tu
di
 d
i M
ila
no
 o
n 
29
/0
7/
20
14
 1
0:
57
:2
2.
 
View Article Online
1338 | Metallomics, 2014, 6, 1336--1345 This journal is©The Royal Society of Chemistry 2014
Cytosolic iron that is not used by phagocytic cells to synthe-
size proteins involved in vital functions can be stored in ferritin
or exported by ferroportin (Fig. 2). The expression of both
proteins is induced by heme and iron. Ferritin is a cytosolic
iron storage protein composed of H and L subunits that are
assembled in various proportions in diﬀerent cells.22 Ferritin
and ferroportin synthesis is controlled post-transcriptionally by
the activity of iron regulatory proteins (IRPs), which regulate
intracellular iron homeostasis by binding to conserved
elements in target mRNAs.23 In the case of ferritin and ferro-
portin, IRP binding activity, which prevents mRNA translation,
is decreased when iron levels are high. However, iron can also
Fig. 1 Iron handling in macrophage subsets performing distinct functions. (A) Clearance of senescent/damaged red blood cells (RBC) is the major
function of macrophages involved in erythrophagocytosis in spleen red pulp and liver (Kupﬀer cells). These cells recycle iron derived from hemoglobin
catabolism through the iron exporter ferroportin (Fpn). (B) During infection and inflammation, pro-inflammatory macrophages sequester iron into
ferritin (Ft) to reduce iron availability to pathogens, at both the systemic and local levels. (C) A diﬀerent population of macrophages (alternatively
activated, M2), which is involved in inflammation resolution and tissue repair, actively internalizes heme iron through CD163, which is then exported
by Fpn. (D) Obesity is associated with a switch of adipose tissue macrophages (ATM) from an M2-like phenotype to an M1-like phenotype; iron retention
may enhance ROS production and pro-inflammatory activity. (E) High iron content in arterial plaque macrophages may lead to increased ROS production
and favor the formation of foam cells and atherosclerotic plaque progression, but the role of iron in this setting is controversial. (F) Osteoclasts are
multinucleated giant cells of the monocyte lineage that are responsible for bone resorption; for this activity they need high energy levels, and thus obtain
a considerable amount of transferrin-bound iron for mitochondrial biogenesis.
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induce ferritin expression at the transcriptional level.24 Moreover,
it has been demonstrated that the heme-activated transcription
factor NRF2, which is key for HO-1 induction,25 is also involved in
the increase of both ferritin H26 and ferroportin transcription.27
Therefore, the molecular basis of the partitioning between storage
and release is presently not completely understood; however, this
phenomenon may be relevant to account for the long-known
biphasic nature of iron release from macrophages, which has
been elegantly described in ferrokinetic experiments. In the initial
phase, part of iron derived from hemoglobin promptly (within
o1 h) returns to circulation, while the remaining iron is released
over the course of days. Interestingly, the amount of iron released
in these two distinct phases can be influenced by erythroid
demand and is altered under pathological conditions.28
The fraction of iron stored in ferritin versus the fraction that
returns to circulation is likely to depend on the still poorly
understood mechanisms that control subcellular iron traﬃc, in
which iron chaperon proteins (e.g., the poly(C) binding proteins)
likely play a role. Although these proteins are important for the
delivery of iron to ferritin and other iron-requiring proteins,29
their function has not been completely characterized.
It has been shown that iron can be transported across the
endolysosomal membrane by the nonselective cation channel
TRPML1,30 but its role in macrophages has not been charac-
terized (Fig. 2).
Release by means of secreted ferritin is another possible fate
that can be hypothesized for macrophage iron (Fig. 2). Although
the source of serum ferritin remains unclear, recent studies
suggest that macrophages contribute significantly to serum
ferritin. The higher serum ferritin levels observed in mice with
macrophage-specific ablation of IRP2 decreased dramatically
after splenectomy;31 moreover, iron accumulation in spleen
and liver macrophages and increased serum ferritin levels are
present in mice with macrophage-specific ferroportin deletion.32
Thus, ferritin secretion might be an important mechanism of
iron transport to circulation and/or within a tissue.
Because an average macrophage recycles one red cell per
day, thus obtaining about 109 iron atoms, erythrophagocytosis
represents the major route of iron uptake for macrophages;
however, these cells can acquire iron by a number of diﬀerent
routes (Fig. 2). Macrophages express transferrin receptor 1
(TfR1), and therefore can internalize transferrin-bound iron,
Fig. 2 Major pathways of iron traﬃcking in macrophages. Macrophages acquire heme iron through ingestion of eﬀete red blood cells and receptor-
mediated internalization of proteins that bind extracellular free heme (interaction of hemopexin with CD91) or hemoglobin (interaction of haptoglobin with
CD163). The heme moieties are degraded by heme oxygenase (HO-1) to release CO, biliverdin and iron, which is delivered by members of the PCBP family
of chaperones to ferritin for storage. Part of heme can be exported through FLVCR1. Macrophages can also obtain iron by transferrin receptor (TfR1)-
mediated endocytosis of diferric transferrin (Tf-Fe), followed by Steap3-dependent reduction and DMT1-mediated transport across the endosomal
membrane. Iron can be transported across the endosomal (and lysosomal) membrane by means of the TRPML1 channel. Macrophages also express the
lipocalin 2 (Lcn2) receptor 24p3R and can thus acquire siderophore-bound iron that has been complexed by Lcn2. Excess iron is mainly exported by
ferroportin in ferrous form, and then oxidized by ceruloplasmin for eﬃcient binding to transferrin, but secretion of iron-loaded ferritin may represent an
alternative route. In macrophages, Nramp1 confers protection against intracellular microbes by exporting iron across the phagosomal membrane.
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which is then reduced by Six-transmembrane epithelial antigen
of the prostate 3 (Steap3) and transported in the cytoplasm by
the divalent metal transporter 1 (DMT1), moreover, they
acquire molecular iron via DMT1, and they also have other
mechanisms to internalize heme iron by means of scavenger
receptors. Haptoglobin binds cell-free hemoglobin (preventing
the release of potentially toxic free heme), and hemopexin
scavenges free heme. The macrophage transmembrane recep-
tor CD163 binds the haptoglobin–hemoglobin complex, while
hemopexin is recognized by low-density lipoprotein (LDL)
receptor-related protein 1 (LRP1/CD9)33 (Fig. 2). Scavenger-
mediated iron uptake can represent an important source of
iron for macrophages under conditions of hemolysis or tissue
damage. Since the storage and release of iron not obtained by
erythrophagocytosis likely follows the same pathways described
above, this issue has not been explored in depth.
Body iron metabolism under inflammatory conditions
As outlined at the beginning of this review, macrophages are
components of innate immunity whose major function is host
defense from pathogens. To this purpose, they possess a variety
of strategies and biological weapons, including the capacity to
modify the expression of proteins involved in iron metabolism
in order to sequester iron, which represents a well known
bacteriostatic mechanism (Fig. 1). In fact, microbes are strictly
dependent on iron availability to grow, and thus are able to
compete very eﬃciently for this essential metal.34 The impor-
tance of this issue has been emphasized recently by studies that
link an increased risk of pathogen-dependent diseases to iron
supplementation programs aimed at preventing iron-deficiency
anemia.34 This competition for iron takes place at both the local
and systemic levels. On one hand, given the large flux of iron
that is processed daily during erythrophagocytosis, splenic and
liver macrophages are primarily involved in the well-known
hypoferremia that accompanies inflammatory conditions. How-
ever, as a side eﬀect, iron accumulation in reticuloendothelial
cells is one of the mechanisms that leads to the development
of anemia associated with chronic inflammation (anemia of
chronic disease, ACD).35 The molecular details of this response
entail inflammatory stimulus-mediated regulation at the tran-
scriptional and post-transcriptional levels of ferroportin (down-
modulated) and ferritin (induced) in macrophages.36 However,
the most important mechanism to reduce serum iron levels
likely relies on the induction of hepcidin by pro-inflammatory
cytokines like IL-6. Increased levels of circulating hepcidin block
ferroportin-dependent iron release from macrophages, which in
turn leads to hypoferremia and low transferrin saturation.3,9,10
Hepcidin induction and sustained hypoferremia require the
Toll-like receptor 4 (TLR4)/MyD88 pathway.37 However, the
response to inflammation is biphasic and the eﬀect of hepcidin
is preceded by an early phase (Myd88-independent) that mainly
involves the direct suppression of ferroportin synthesis, which
might be accompanied by the increased removal of circulatory
iron through enhanced uptake via TfR1.38 The key role of
elevated hepcidin levels in the pathogenesis of ACD has been
demonstrated by studies showing that hepcidin overexpression
in mice and humans is associated with iron retention in macro-
phages and hypoferremia, leading to functional iron deficiency
and ACD.3,9,10,35 As a consequence, there has been great interest
in developing hepcidin inhibitors as a new therapeutic strategy
for treating ACD (reviewed in Sun39).
Macrophage iron metabolism during infection
Iron sequestration by macrophages also occurs in the inflam-
matory microenvironment, where monocyte-derived macro-
phages recruited by inflammatory signals and activated
resident macrophages face invading pathogens. In this context,
the same machinery that operates to restrict systemic iron
availability is at work; other specific mechanisms also act to
sequester iron at the local level. Hepcidin is produced by
macrophages at the site of infection by a lipopolysaccharide
(LPS)-induced and TLR4-dependent pathway40,41 that also
involves bone morphogenetic protein (BMP) signalling,42 and
may represent an additional way to eﬃciently repress
ferroportin-mediated iron export. On the other hand, recent
studies shed light on the role of ferroportin in macrophages
challenged by intracellular bacteria (e.g., Salmonella). In fact,
ferroportin down-modulation with consequent intra-macro-
phage iron accumulation would spur intracellular pathogen
growth.43 In agreement with this concept, hemochromatosis,
which is characterized by hyperferremia and concomitant macro-
phage iron depletion, is associated with greater susceptibility to
extracellular pathogens and resistance to intracellular patho-
gens.43 Therefore, it is notable that recent studies have shown
that nitric oxide (NO) production stimulates Nrf2-dependent44
ferroportin expression and iron export in Salmonella-infected
macrophages,45 possibly as a countermeasure to limit hepcidin-
mediated ferroportin down-modulation. This finding represents a
novel mechanism underlying the recognized antimicrobial role of
NO. In the same vein, treatment with the calcium channel blocker
nifedipine has been shown to induce ferroportin expression in the
spleen, thereby mobilizing tissue iron and enhancing host resis-
tance to intracellular pathogens.46 In this context, ferroportin
polymorphisms identified in humans and resulting in impaired
interaction with hepcidin can lead to decreased macrophage iron
content, while iron accumulation is observed in individuals with
alterations that lead to defective iron export. Evidence from
in vitro experiments (and limited but interesting epidemiological
studies) suggests that ferroportin polymorphisms can aﬀect the
host’s response to intracellular and extracellular bacteria
(reviewed in Kasvosve47).
Pathogens utilize a variety of strategies to acquire iron from
the environment despite its poor bioavailability; these mechan-
isms include extracellular iron mobilization, uptake and intra-
cellular assimilation.48,49 Among the various strategies that a
large number of bacteria employ to obtain iron, a significant
role is played by the secretion of siderophores, small molecules
that bind ferric iron from several sources with high aﬃnity.
Iron-siderophore complexes are then internalized, and specific
and sophisticated iron release mechanisms are then used to
make iron available for metabolic purposes.49
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In this context, the relevant role of lipocalin2 (Lcn2, also
named siderocalin, Neutrophil gelatinase-associated) is well
known. Lcn2 is a protein that binds iron-loaded bacterial
siderophores,50 and thus is essential in defending the host
from extracellular pathogens.51 The Lcn2–siderophore complex
can be transported across the cell-membrane by receptor-
mediated endocytosis via the receptors 24p3R52 (Fig. 2). Recent
studies have indicated that the protective action of Lcn2 is also
important against intracellular pathogens. Experiments with
macrophages obtained from Lcn2-deficient mice revealed that
Lcn2 is required in order to limit the amount of iron available
to Chlamydia pneumoniae and hence curb bacterial growth.53
Interestingly, in the absence of Lcn2, the host increases IL-10-
dependent ferritin synthesis as an alternative protection
mechanism.
Recent data suggest that the antimicrobial action of
Nramp1, a cation transporter located in late phagolysosomes
that confers resistance to infection with several intracellular
pathogens,54 is caused by its recognized role in decreasing the
availability of iron for intraphagosomal bacteria, and also
results from interplay with Lcn2. In fact, Nramp1 increases
Lcn2 expression through an NF-kB-mediated transcriptional
mechanism that eventually confers protection against the
intracellular bacterium S. typhimurium.55 A novel role, possibly
not linked to its siderophore binding activity, was recently
established for Lcn2 as a determinant of macrophage deactiva-
tion, a process that has been linked to the resolution phase of
inflammation and is important for the outcome of bacterial
infections. Lcn2, which is a marker of deactivated macrophages
and is induced in patients with bacterial pneumonia, stimu-
lated IL-10 production, thus impairing the immune response to
Streptococcus pneumoniae.56 This role of Lcn2 apparently does
not depend on its iron binding capacity, because S. pneumoniae
does not use siderophores to acquire iron.
Metalloreductase Steap3, which is expressed at high levels in
macrophages, is another protein that is important in regulating
both iron homeostasis and TLR4-mediated inflammatory
responses in macrophages (Fig. 2). Steap3 is a ferrireductase
that transforms ferric iron derived from internalized transferrin
to ferrous iron, which is the only form that can be transported
to the cytoplasm.57 The down-regulation of Steap3 after LPS
stimulation leads to iron accumulation in endosomes and
lysosomes, accompanied by decreased cytosolic iron (a requi-
site for iron sequestration during inflammation). Furthermore,
Steap3 appears to be important for the TLR4-mediated induc-
tion of inflammatory proteins.58
Iron metabolism and macrophage polarization
It is now increasingly recognized that macrophages can
undergo classic pro-inflammatory (M1) or alternative (M2)
polarization in response to various environmental and immune
signals, and that these polarized cells have completely diﬀerent
biological properties.59 Classical activation (e.g., by microbial
agents) is associated with the production of ROS and pro-
inflammatory cytokines, and results in cytotoxicity and high
microbicidal capacity; M2 polarisation is triggered by cytokines
like IL-4 or IL-13,1,59 and results in cells that are important in
the immune response to parasites and allergic stimuli. More-
over, M2 cells act in the regulation of adaptive immunity and in
the control of cell growth and tissue remodelling during the
resolution phase of the inflammatory process.
Recent studies have shown that these two populations are
also characterized by the divergent expression of the major
proteins of iron homeostasis and very diﬀerent iron hand-
ling.60,61 Contrary to the iron-sequestering activity of pro-
inflammatory M1 cells, M2 macrophages express low levels of
the iron storage protein ferritin and actively export iron via
ferroportin (Fig. 1). This diﬀerence between M1 and M2 activity
results in large diﬀerences in both intracellular and extra-
cellular iron availability, which may in turn aﬀect macrophage
functions.36 The functional implications of this M2 macro-
phage activity regarding increasing iron availability in the
microenvironment under specific pathophysiologic conditions
have been recently discussed.48 The high capacity to internalize
and detoxify heme iron (through CD163 and HO-1, respectively)
is another characteristic of M2 macrophages62 that appears to
be important under conditions characterized by bleeding and
the accumulation of toxic heme iron.63
In addition to their distinct roles in the inflammatory
response, diﬀerently polarized macrophage populations appear
to have specific functions in other pathological settings, such
as obesity and atherosclerosis.
Emerging role of iron in the
functioning of particular types of
macrophages
Atherosclerotic plaque macrophages
The macrophage is a key cell type in the formation and fate of
atherosclerotic plaques, eventually evolving into a foam cell. A
number of studies have recently elucidated the role of excess
macrophage iron in atherosclerotic plaques (reviewed by Sullivan64)
(Fig. 1). In fact, iron catalyzes ROS generation, and might therefore
promote lipid oxidation and contribute to atherosclerotic plaque
instability. Indeed, human atherosclerotic plaques contain approxi-
mately 10-fold more iron than healthy arteries, although probably
with large variations in distribution.65
Intraplaque hemorrhage, which promotes the progression and
destabilization of atherosclerotic lesions, may be a source of iron.
In this context, expression of CD16366 andHO-167 inmacrophages
exerts beneficial roles: CD163 internalizes potentially toxic heme
from the microenvironment, which in turn stimulates cholesterol
export; and HO-1 degrades the heme moiety. Recent reports have
provided evidence in favor of the so-called ‘‘iron hypothesis’’,
which envisages a role for macrophage iron in the progression of
atherosclerosis. In particular, a role has been suggested for
hepcidin, which promotes plaque destabilization after erythro-
phagocytosis.68 Accordingly, reduction of macrophage iron con-
tent (obtained by inhibiting hepcidin, and thereby increasing
ferroportin-mediated iron export) stimulated cholesterol eﬄux
and prevented atherosclerosis in mice.69 Importantly, hepcidin
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levels and macrophage iron content correlated with vascular
damage in monocytes of patients with a high risk of developing
cardiovascular disease.70 Moreover, despite small divergences
likely related to slightly diﬀerent methodological procedures, a
number of studies69,71,72 similarly reported that macrophages
that exhibit an M2-like phenotype characterized by ferroportin-
dependent iron release are atheroprotective (discussed in
Hasty73). An interesting interplay between lipid and iron traﬃc
in macrophages also emerges from these studies. Liver X recep-
tors a71 and b,72 which are known to promote lipid eﬄux and
decrease inflammation, induce both iron release and cholesterol
export,69 possibly preventing lipid oxidation and foam cell
formation; this mechanism may represent a novel atheroprotec-
tive strategy. In contrast to these reports, which suggest that iron
accumulation in plaque macrophages is harmful, a recent work
failed to demonstrate that hepcidin and macrophage iron act in
atherosclerotic lesion formation,74 in agreement with a previous
report showing a modest eﬀect of iron chelation on athero-
sclerotic plaque development.75 These contrasting results may
be related to diﬀerences in study design, such as the way of
inducing iron overload (defective ferroportin-mediated iron
export and/or parenteral iron injection vs. erythrophagocytosis
associated with hemorrhage) and therefore the type of iron (non-
heme vs. heme). In addition to modulating the properties of
macrophages inside the atherosclerotic plaque, the finding that
monocyte iron loading increases adhesion to the endothelium76
suggests that iron may also act during an earlier phase of
atherosclerotic lesion progression.
Most tissues contain resident macrophages that are often
involved in immune surveillance; however, their involvement in
other functions is increasingly recognized.77 Recent studies
have indicated that iron appears to be involved in the functions
of at least two particular types of resident macrophages:
adipose-tissue-associated macrophages (ATMs) and osteoclasts.
Osteoclasts
Osteoclasts, which derive from mononuclear precursors of the
macrophage lineage, are multinucleate cells involved in bone
resorption, and are centrally involved in skeletal growth and
remodeling, as well as in calcium homeostasis.78 Recent work
suggests that iron is important for bone formation, particularly for
osteoclast diﬀerentiation and activation (Fig. 1). TfR1-mediated
iron uptake79 and reduction of Fe3+ by the ferrireductase Steap
family member 4 (ref. 80) are essential for osteoclastogenesis: iron
is necessary for the biogenesis of mitochondria, which are
required to sustain the high energy demand of osteoclasts. On
one hand, iron serves for the synthesis of numerous heme and
iron–sulfur-containing mitochondrial proteins; on the other hand,
iron favors the production of nontoxic levels of ROS, which in turn
act as signaling molecules to activate factors that stimulate
mitochondrial biogenesis (e.g., CREB and PGC-1b). While iron is
required to maintain correct bone remodeling, it is clear that, by
leading to increased ROS production,81 iron excess may shift the
balance between deposition and resorption in favor of the latter,
thus explaining the well-known association between iron overload
and osteoporosis.82 These studies provide new insights that
correlate this bone defect that is typical of iron overload diseases
with excessive osteoclastic activity, and open the way to possible
therapeutic strategies based on iron chelators and/or antioxidants.
Adipose tissue-associated macrophages
The contribution of the immune system to obesity has been
increasingly appreciated. In obesity, adipocytes increase the
recruitment of macrophages to adipose tissue (ATMs) with a
concomitant shift in the activation state of macrophages from an
anti-inflammatoryM2 state towards an inflammatory M1 state. In
turn, inflammatory M1 macrophages impair the function of
adipose cells and trigger metabolic alterations, such as insulin
resistance and liver pathology.83 The link between iron and
energy homeostasis at the systemic level is also increasingly
recognized (reviewed in Simcox84), as iron deficiency is associated
with obesity, and iron overload increases diabetes risk by directly
damaging pancreatic cells, as well as by increasing insulin
resistance, possibly through adiponectin downregulation.85
Moreover, hepcidin was recently identified as a link between iron
metabolism and glucose homeostasis,86 as well as nutrient
status.87 At the cellular level, mammalian target of rapamycin
(mTOR), a major sensor and controller of the metabolic state of
the cell, has also been shown to regulate cellular iron home-
ostasis.88 In this context, a recent study analyzed ironmetabolism
in ATMs for the first time,89 and identified a population of iron-
rich macrophages that also exhibit an M2-like expression profile
(Fig. 1). Interestingly, the proportion of these cells with respect to
iron-poor macrophages and their iron storage capacity were
decreased in obese mice, concomitant with iron accumulation
in adipocytes, which suggests complex iron traﬃcking among the
cellular components of adipose tissue.
Conclusion
It is becoming clear that macrophages are part of a continuum
that spans a range of phenotypes and functions that are largely
dictated by the microenvironment. This heterogeneity also con-
cerns iron handling, which clearly diﬀers among the various
macrophage subpopulations. Defining the mechanisms of macro-
phage iron traﬃcking, which is a non-secondary function of these
cells, will oﬀer insights into the roles of distinct macrophage
subtypes in a number of pathophysiological settings, and will also
provide opportunities to explore possible therapeutic approaches
by manipulating macrophage activity. For example, it will be
possible to modulate ferroportin-mediated iron export from
macrophages by targeting hepcidin with antagonists or agonists
that have been characterized in pre-clinical models,39 or to use
recent technologies90 to specifically deliver a macrophage-selective
pharmacological eﬀect.
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